The effect of intravenous hydration strategy on plasma methotrexate clearance during intravenous high-dose methotrexate administration in pediatric oncology patients

Abstract

Intravenous hydration of ≥3,000 mL/m²/day during HD-MTX administration is essentially required in osteosarcoma and can be considered as optional in ALL with HD-MTX <1.5 g/m², especially in developing countries with limited monitoring of plasma methotrexate level.